UK-based Porton Biopharma has opened a new multi-million dollar pharmaceutical manufacturing facility to increase the capacity of its existing production center used for making the cancer drug Erwinase, a drug that is mostly used to treat childhood leukaemia. Based at Porton Down in Wiltshire, UK, the company was commercialized out of Public Health England (PHE) in April 2015. In addition to Erwinase, Anthrax Vaccine was developed at the Porton Down site as well as other products including Dy...